Purpose of review: Brain metastases are frequent complication of lung cancer and are associated with poor prognosis. Patients with brain metastases secondary to lung cancer have traditionally been managed with surgery and radiation with limited role for systemic chemotherapy. In the past decade, however, this paradigm has shifted largely due to the advent of targeted therapies and immunotherapies, both of which have demonstrated efficacy in the treatment of brain metastases and extracranial disease.
Recent findings: While patients with brain metastases secondary to lung cancer have historically been excluded from trials, recent data suggest efficacy of novel targeted therapies and immunotherapies in these patients. In fact, there are multiple ongoing trials to further evaluate these therapies in this patient profile. Targeted therapies and immunotherapies have the potential to improve outcomes in patients with brain metastases secondary to lung cancer.
Keywords: ALK; Brain metastases; Clinical trials; EGFR; Immunotherapy; Lung cancer; Targeted therapy.